$815 Million is the total value of Parkman Healthcare Partners LLC's 99 reported holdings in Q1 2024. The portfolio turnover from Q4 2023 to Q1 2024 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VYNE THERAPEUTICS INC | $2,138,163 | +31.8% | 696,470 | 0.0% | 0.26% | +14.4% | ||
| ETON | ETON PHARMACEUTICALS INC | $746,880 | -14.4% | 199,168 | 0.0% | 0.09% | -25.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DEXCOM INC | 19 | Q2 2024 | 6.3% |
| XENON PHARMACEUTICALS INC | 19 | Q2 2024 | 3.3% |
| SCHRODINGER INC | 18 | Q2 2024 | 4.2% |
| MANNKIND CORP | 18 | Q2 2024 | 1.7% |
| INSULET CORP | 17 | Q2 2024 | 4.8% |
| AVID BIOSERVICES INC | 17 | Q2 2024 | 2.9% |
| ARCUS BIOSCIENCES INC | 17 | Q2 2024 | 2.1% |
| ACLARIS THERAPEUTICS INC | 16 | Q3 2023 | 10.0% |
| NATERA INC | 16 | Q3 2023 | 3.4% |
| SUTRO BIOPHARMA INC | 16 | Q2 2024 | 1.9% |
View Parkman Healthcare Partners LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PLUS THERAPEUTICS, INC. | February 13, 2023 | 583,467 | 1.7% |
View Parkman Healthcare Partners LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-08-14 |
| N-PX | 2024-08-01 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-13 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Parkman Healthcare Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.